SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESH Acquisition Corp. (ESHA) is trending amidst heightened market attention for low-float SPACs, with traders noting its exceptionally tight share structure and high insider ownership. Community discussion points to significant institutional accumulation and views ESHA as having substantial potential for rapid upward movement, drawing comparisons to other recent high-flying low-float plays.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending due to widespread discussion around year-end tax loss selling and persistent selling from early investors, which is currently driving significant downward pressure. Community sentiment remains sharply divided, with some seeing current levels as a compelling buying opportunity given the company's profitability and growth, while others emphasize ongoing dilution concerns and a challenging market backdrop.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending due to the recent FDA approval of NEREUS (tradipitant), marking the first new motion sickness drug in over four decades. The community is actively discussing its potential to alleviate GLP-1 induced nausea, viewing this as a significant market opportunity and a catalyst for potential buyouts. While some initially expressed mixed reactions to price action, many believe the stock's long-term value and additional pipeline catalysts are not yet fully reflected.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending amidst intense speculation regarding an unconfirmed FDA decision on its relacorilant drug for Cushing's Syndrome, with community chatter divided between rumored rejection causing panic selling and calls to buy the dip. The immediate uncertainty around this key pipeline asset, alongside its existing revenue-generating drug Korlym and other promising indications like ovarian cancer, fuels a volatile debate among investors.

Aimei Health Technology Co., Ltd. is a blank check company, which engages in entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on April 27, 2023 and is headquartered in New York, NY.

Aimei Health Technology Co Ltd

Aimei Health Technology ($AFJK) is trending due to extreme volatility, attributed to its low float and a recent short squeeze that broke a month-long downtrend. The community is actively debating its "pump and dump" nature and "casino play" characteristics, comparing it to other highly volatile low-float names like $ESHA and $SMX, as it continues to see significant price movements and trading halts.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is actively discussed amid a repeatedly delayed shareholder vote to increase authorized shares, sparking a tug-of-war between those who see it as necessary for strategic acquisitions like Ask Sage and securing major government AI contracts, and those concerned about potential dilution. Community sentiment is also driven by discussions of robust government and defense sector opportunities, insider buying, and technical analysis, with many anticipating significant developments ahead for this pure-play AI defense contractor.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as recent analyst reports highlight anticipated weaker transaction revenue, largely due to soft crypto trading volumes. This news compounds investor frustration over the stock's recent downtrend, with many speculating on year-end tax-loss selling and the platform's widely discussed, yet often disappointing, holiday giveaways. The community is actively debating Robinhood's correlation to crypto market volatility and its positioning within the broader fintech landscape.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is gaining significant attention following a regulatory setback for a competitor's Cushing's syndrome drug, Corcept Therapeutics (CORT), which received a Complete Response Letter from the FDA. This news alleviates immediate competitive pressure on Xeris's Recorlev, positioning it for an extended period of market leadership. The community is actively debating the long-term implications for Recorlev's market share and XERS's perceived undervaluation in light of this favorable development.

Redacted is a multi-vertical Web3 ecosystem focused on bridging Real-World Assets (RWA) with on-chain accessibility. It powers products across RWA, DeFi, GameFi and Creator Platforms through its ecosystem token $RDAC. Following its merger with Tenset in October 2025, Redacted became the ecosystem layer uniting token launches and RWA participation under a single, scalable framework serving both institutional and retail users.

Redacted

RDAC is trending due to recent corporate actions, including an amendment to its trust agreement and significant redemptions, which the community believes has drastically reduced its public float. Traders are actively discussing the potential for a short squeeze and comparing it to other recent "SPAC mania" runners, anticipating a similar explosive move given the perceived low share count.

Alchemy Investments Acquisition Corp. 1 is a blank check company, which engages in merger, share exchange, asset acquisition, share purchase, and reorganization or similar business combination. The company was founded on October 27, 2021 and is headquartered in Newark, DE.

Alchemy Investments Acquisition Corp 1 - Ordinary Shares - Class A

Alchemy Investments Acquisition Corp 1 (ALCY) is garnering significant attention following its non-binding Letter of Intent to merge with Cartiga, LLC, a litigation finance asset management platform. The community is actively discussing the stock's notably low float and increased trading volume, with many anticipating potential rapid price movements similar to other recently active SPACs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SLS Daily Reminder: AZA+VEN the BAT - Best Available Treatment for SLS Phase 3 Control Arm Patients RECENTLY FAILED 3 Large Phase 3 Trials: 
VIALE-M FAILED in AML CR1 Maintenance 
VIALE-T FAILED in AML Post Stemcell Maintenance 
VERONA  FAILED in MDS/AML Precursor  
- ALL FAILED DUE TO TOXicity 
Key Fact: $ABBV $BMY $RHHBY who own Azacitidine and Venetoclax - 
- these 3 Large A** Pharma, Know Right Now, Gps is wholly responsible for the Miraculous Survival of these Aml Second remission patients.   
  
They know precisely how their drugs perform - these are the 3 Likely to Be Bidding Now while SLS is Still Massively Undervalued.  
  
Ps. does everyone know, SLS a 14 FTE Drug Development co, eliminated the entire direct commercialization team in March of last year - ? the entire Pharma Industry Knows SLS is on the Block and the Clock is ticking.

EasyLode

Marco F

Money Mikey

GPs 24 / Control 8

Captain

YEHMINGZHU

bjarki johannes

Chessdoc

Robert

CMSP

$SLS Aza+VEN is the Best Available Treatment for Control Arm Patients - and it Failed 3 Large Phase 3 Trials due to Toxicity. 
 
in the VIALE-A Trial 83% Aza VEN Patients Suffered Serious Adverse Events and 23% of the Patients Taking AzaVEN DIED from TAKING AzaVEN. 
 
BAT for Control Arm patients is toxic, just like Dr. Levy, Dr. Jamy and Dr. Tsirigotis stated - and MOS is DISMAL.

StockTwits Web

SELLAS Life Sciences Group Inc

$SLS $ABBV $BMY $RHHBY The Kennedy Woman probably was on this treatment. God rest her soul 🙏

StockTwits For Android 

Abbvie Inc

Bristol-Myers Squibb Co.

Roche Holdings AG ADR

 Daily Reminder: AZA+VEN the BAT - Best Available Treatment for SLS Phase 3 Control Arm Patients RECENTLY FAILED 3 Large Phase 3 Trials: 
VIALE-M FAILED in AML CR1 Maintenance 
VIALE-T FAILED in AML Post Stemcell Maintenance 
VERONA  FAILED in MDS/AML Precursor  
- ALL FAILED DUE TO TOXicity 
Key Fact: 

 who own Azacitidine and Venetoclax - 
- these 3 Large A** Pharma, Know Right Now, Gps is wholly responsible for the Miraculous Survival of these Aml Second remission patients.   
  
They know precisely how their drugs perform - these are the 3 Likely to Be Bidding Now while SLS is Still Massively Undervalued.  
  
Ps. does everyone know, SLS a 14 FTE Drug Development co, eliminated the entire direct commercialization team in March of last year - ? the entire Pharma Industry Knows SLS is on the Block and the Clock is ticking.